Raynaud's Disease
16
1
1
14
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
50%
8 trials in Phase 3/4
14%
2 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (16)
Open Label Treprostinil Raynaud's Study
Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease
A Two-Part Study of BOTOX® Therapy for Ischemic Digits
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
PF-00489791 For The Treatment Of Raynaud's
Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon
Nova Cold Hands Raynaud's Disorder, a Disease Which Results in Decreased Blood Flow to the Hands and Feet.
Raynaud's Treatment Study (RTS)
A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
St. John's Wort in the Treatment of Raynaud's Phenomenon
Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon
Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon
Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon